Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | EDNRB | P24530 | 2/20 | 0.41 |
| ▸ | EDNRA | P25101 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601750 | 0.91 | ALDH1A1 (0.48) | ALDH1A1HTTLMNANPSR1KDM4E | |
| SCHEMBL2601749 | 0.89 | ALDH1A1 (0.47) | ALDH1A1HTTLMNANPSR1KDM4E | |
| SCHEMBL2605617 | 0.85 | DPP4 (0.49) | ALDH1A1HTTLMNANPSR1KDM4E | |
| SCHEMBL2601755 | 0.82 | ALDH1A1 (0.45) | ALDH1A1HTTLMNANPSR1KDM4E | |
| SCHEMBL2601748 | 0.81 | TDP1 (0.44) | ALDH1A1HTTLMNANPSR1MEN1 | |
| SCHEMBL1723606 | 0.81 | ALDH1A1 (0.41) | ALDH1A1HTTLMNANPSR1KDM4E | |
| SCHEMBL14522319 | 0.81 | DPP4 (0.43) | ALDH1A1HTTLMNANPSR1MEN1 | |
| SCHEMBL1724918 | 0.79 | SLC6A5 (0.41) | ALDH1A1HTTLMNANPSR1MEN1 | |
| SCHEMBL1725627 | 0.78 | USP2 (0.39) | ALDH1A1HTTLMNANPSR1MEN1 | |
| SCHEMBL19705382 | 0.78 | HTT (0.40) | ALDH1A1HTTLMNANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179789-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-12-14 | — | — | US | disclosed |
| US-9562051-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562051-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2403856-B1 | METHYLENEDIOXYBENZO [I]PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | UNIV RUTGERS (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2403856-B1 | METHYLENEDIOXYBENZO [I]PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | UNIV RUTGERS (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-04-26 | — | — | US | disclosed |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-04-26 | — | — | US | disclosed |
| WO-2010102219-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179789-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | TOP2B, TOP1, TOP2A | ALDH1A1 1190/4885HTT 1894/4885LMNA 1016/4885 |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | TOP2B, TOP1, TOP2A | ALDH1A1 1190/4885HTT 1894/4885LMNA 1016/4885 |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | TOP2B, TOP1, TOP2A | ALDH1A1 1190/4885HTT 1894/4885LMNA 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.